Assessment of measurement properties of peak VO2in children with pulmonary arterial hypertension

Table 2 Correlation of percentage change (baseline to end of treatment) in peak VO ₂ with other measures

	n	Pearson correlation (95% CI)	Pvalue	Spearman correlation (95% CI)	Pvalue
Physician global assessment of change	106	0.41 (0.24 to 0.56)	<0.0001	0.40 (0.22 to 0.55)	<0.0001
WHO FC
Baseline FC I*	27	0.40 (0.03 to 0.68)	0.04	0.41 (0.04 to 0.69)	0.03
Baseline FC II*	56	0.10 (−0.17 to 0.36)	0.45	0.03 (−0.24 to 0.29)	0.84
Baseline FC III	21	0.52 (0.11 to 0.78)	0.02	0.61 (0.24 to 0.82)	<0.01
Family Cohesion domain	83	0.04 (−0.18 to 0.25)	0.71	0.06 (−0.16 to 0.27)	0.57
Subject global assessment of change	104	0.12 (−0.07 to 0.31)	0.21	0.13 (−0.06 to 0.31)	0.19

CI = confidence interval; Family Cohesion domain = Family Cohesion domain of the Child Health Questionnaire [12]; n = sample size; VO₂ = oxygen consumption; WHO FC = World Health Organization Functional Class.
*For patients with WHO FC II or I at baseline, there was little (FC II) or no (FC I) room for improvement in WHO FC. Thus, care needs to be taken with the interpretation of their data. For those with WHO FC I at baseline, only 4 patients deteriorated from baseline; for those with WHO FC II at baseline, none deteriorated and 8 improved from baseline.